|
|
|
|
|
| FOLFIRI with BVZ November 2008 to March 2009 | Regional radiology CT October 2009 | Recurrence |
|
|
|
|
|
|
|
|
| Phase II study with panitumumab February 2010 |
|
|
|
|
|
|
|
|
|
|
| Single agent trial-placebo February 2010 to August 2010 | Regional radiology CT August 2010 | Recurrence |
|
|
|
|
|
|
|
|
| Panitumumab August 2010 to February 2011 | Regional radiology CT February 2011 | Recurrence |
|
|
|
|
|
|
|
|
| Irinotecan and panitumumab February 2011 to May 18, 2011 | Cancer institute CT August 19, 2011 | Recurrence |
|
|
|
|
|
|
|
|
| BC. September 22, 2011 PB, erlotinib, capecitabine, oxaliplatin, BVZ, pazopanib |
|
| Regional radiology CT December 16, 2011 | PR | VEGF, EGFR, HER-2-elevated (blood), BRAF and KRAS-wild-type, PTEN and TS-reduced, MGMT-negative (Caris-tissue analysis) |
| 15 | Regional hospital April 2006 | Adenocarcinoma of the colon, moderately differentiated | Regional hospital CT January 12, 2009 | Nodules in the lungs | Colectomy April 2006 |
|
|
|
|
|
|
| January 13, 2009 (lung nodule biopsy) | Adenocarcinoma, moderately differentiated of colonic origin |
|
| Capecitabine June 2006 to November 2006 | Regional radiology CT January 12, 2009 | Recurrence (lungs) |
|
|
|
|
|
|
|
|
| Capecitabine, oxaliplatin, BVZ February 17, 2009 to August 2009 |
|
|
|
|
|
|
|
|
|
|
| Capecitabine, irinotecan, BVZ. February 2010 to August 2010 | Regional radiology CT January 18, 2011 | Recurrence (lungs) |
|
|
|
|
|
|
|
|
|
| Regional radiology CT September 14, 2011 | Recurrence (lungs) |
|
|
|
|
|
|
|
|
| BC. December 13, 2011 PB, pazopanib, everolimus, dasatinib |
|
| Regional radiology March 13, 2012 | SD | VEGF-elevated (blood), ERCC1, TS, and PTEN-negative, SRC, PDGFRB, and HIF1A-overexpressed, VHL-reduced, BRAF-wild-type, (Caris-tissue analysis) |